A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

Trial Profile

A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 May 2017

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms FIR
  • Sponsors Genentech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Pooled results of three phase II trials (POPLAR, BIRCH and FIR) assessing Tumor mutation load (ML) and its association with atezolizumab efficacy were presented at the 41st European Society for Medical Oncology Congress
    • 02 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top